Our patented TILT® technology, based on oncolytic viral therapies, modifies the tumour microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.
We have multiple best-in-class oncolytic viral therapies. In our pipeline, our lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe.
Our pioneering approach has been recognized by industry leaders including Germany’s Merck KGaA and the USA’s Pfizer (Merck-Pfizer Alliance), MSD International GmbH, and Biotheus, a privately held Chinese biotechnology company.
“Our vision is to become the leading company globally in oncolytic immunotherapy for enabling therapies based on T cells, such as immune checkpoint inhibitors and adoptive cell therapies, thereby providing potentially curative treatment options for cancer patients.”